Baxter's North Carolina Facility Manufactures ~60% Of IV Fluids And Peritoneal Dialysis Solutions, Senator Demands Immediate Action To Protect Patient Care Amid Shortage

Benzinga
2024-10-10

U.S. Senator Amy Klobuchar (D-MN) is calling on U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra to utilize all available resources to tackle the national shortage of intravenous (IV) solutions.

This crisis follows the shutdown of Baxter International’s (NYSE:BAX) largest IV solutions manufacturing facility due to flooding from Hurricane Helene.

With Hurricane Milton looming, Senator Klobuchar warns that another facility in Daytona Beach, Florida, may also be at risk, worsening the current situation.

The Baxter facility is responsible for manufacturing approximately 60% of IV fluids and peritoneal dialysis solutions available to health care providers in the U.S.

Senator Klobuchar expressed deep concern over the implications of this shortage on patient care.

“Flooding from Hurricane Helene compromised the safe operations, inventory, raw materials and roadway access at Baxter International’s intravenous (IV) solution plant in Marion, North Carolina,” wrote Senator Klobuchar. 

“As a result of Hurricane Helene, hospitals, dialysis centers, and other health care providers around the country—including many in Minnesota—are already being forced to ration these basic, but life-saving supplies.” 

To mitigate the impact of this critical shortage, Klobuchar urged the HHS to act swiftly, coordinating with the Federal Trade Commission and the Department of Justice to prevent the distribution of counterfeit IV solutions.

She called for measures to safeguard against price gouging and other illegal practices by companies marketing FDA-approved IV solutions.

Klobuchar stressed that no single entity should dominate the supply of such vital medical resources, as this poses a significant risk to national health and safety.

The senator’s efforts to combat drug shortages are not new.

The German healthcare group Fresenius SE (OTC:FSNUF) announced that its generic hospital drugs division, Fresenius Kabi, has recently commenced the production of intravenous (IV) solutions at a new facility in Wilson, North Carolina.

Additionally, Reuters highlighted the company is exploring options to expedite the launch of additional production lines at this unaffected site.

Fresenius said increasing U.S. production at the Wilson facility will take several months, but it won’t be sufficient to offset a prolonged shutdown at Baxter.

Price Action: BAX stock is up 2% at $37.87 at last check Wednesday.

Read Next:

  • Honeywell Expands Qualcomm Partnership: AI And Connectivity To Supercharge Energy Industry Operations.

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

  • BAXTER INTL (BAX): Free Stock Analysis Report

This article Baxter's North Carolina Facility Manufactures ~60% Of IV Fluids And Peritoneal Dialysis Solutions, Senator Demands Immediate Action To Protect Patient Care Amid Shortage originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10